Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Cancer Diagnostics

In oncology, biomarkers have many applications, including risk assessment, screening, differential diagnosis, determination of prognosis, response to treatment, and monitoring progression of the cancer. In this session we will highlight the current state of predictive biomarkers for oncology including recent successes, lessons learned, and challenges to come. Among the topics to be discussed are novel clinical trial designs for personalized medicine, emerging predictive biomarkers in immune-oncology trials, lessons learned from PD-L1 as an as an immunotherapy biomarker, and the path forward for next generation sequencing in cancer diagnostics.


Ann Kapoun, Ph.D., Vice President of Translational Medicine, Oncomed Pharmaceuticals

Ann Kapoun is Vice President of Translational Medicine at OncoMed Pharmaceuticals. Her expertise is in the clinical execution and implementation of biomarkers and patient stratification approaches. Dr. Kapoun served as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA / Johnson & Johnson. Read Full Bio

Laura Esserman, M.D., M.B.A., Director, Carol Franc Buck Breast Care Center, Professor of Surgery and Radiology, University of California, San Francisco, Associate Director, UCSF Helen Diller Family Comprehensive Cancer Center

Laura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment. Since 2002 she has led the I-SPY TRIALS, a groundbreaking national public-private collaboration among NCI, FDA, more than 20 cancer research centers and major pharma and biotech companies. Read Full Bio

Web Analytics